ZBP1 and neoplasm: The platform's therapeutic efficacy is achieved through two distinct mechanisms: high‐concentration ROS, activated under specific ultrasonic conditions, synergizes with the upregulation of ZBP1 expression to co‐activate the necroptotic pathway, inducing tumor cell death and effectively eliminating residual cancer cells.